Linda M. Rasmussen

Gentofte, Denmark

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications

Allergic rhinoconjunctivitis

Allergic rhinoconjunctivitis

Journal: Ugeskrift for laeger
Published: May 26, 2026

Five-year inhaled, systemic, and total corticosteroid exposure reduction during anti‒interleukin-5 receptor alpha treatment for severe asthma.

Five-year inhaled, systemic, and total corticosteroid exposure reduction during anti‒interleukin-5 receptor alpha treatment for severe asthma.

Journal: Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology
Published: January 21, 2026

Societal and personal financial burden of severe asthma and impact of biologic therapy: a 19-year nationwide cost analysis.

Societal and personal financial burden of severe asthma and impact of biologic therapy: a 19-year nationwide cost analysis.

Journal: BMJ open respiratory research
Published: October 14, 2025

Financial burden of productivity loss in severe asthma and impact of biologic therapy.

Financial burden of productivity loss in severe asthma and impact of biologic therapy.

Journal: Pulmonology
Published: July 21, 2025

Cumulative corticosteroid burden over 25 years in patients initiating biologic therapy for severe asthma: a nationwide cohort study.

Cumulative corticosteroid burden over 25 years in patients initiating biologic therapy for severe asthma: a nationwide cohort study.

Journal: ERJ open research
Published: May 29, 2025

Biologic Prescription Patterns and Biomarker Determinants of First-Line Dupilumab in Danish Adult Patients With Severe Asthma and Comorbid Atopic Dermatitis.

Biologic Prescription Patterns and Biomarker Determinants of First-Line Dupilumab in Danish Adult Patients With Severe Asthma and Comorbid Atopic Dermatitis.

Journal: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology
Published: May 07, 2025

Long-term efficacy but rare sustained remission: individual-level 5-year stability in anti-IL5/Rα biologic therapy response for severe asthma.

Long-term efficacy but rare sustained remission: individual-level 5-year stability in anti-IL5/Rα biologic therapy response for severe asthma.

Journal: The European respiratory journal
Published: May 03, 2025

Tezepelumab in Real-Life Practice: Characteristics of Patients Commenced and Efficacy in a Nationwide, Danish Cohort of Patients With Severe Asthma.

Tezepelumab in Real-Life Practice: Characteristics of Patients Commenced and Efficacy in a Nationwide, Danish Cohort of Patients With Severe Asthma.

Journal: The journal of allergy and clinical immunology. In practice
Published: February 20, 2025

Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register.

Clinical response and remission in patients treated with dupilumab for severe asthma: Results from the nationwide Danish Severe Asthma Register.

Journal: Respiratory medicine
Published: February 07, 2025

Supratherapeutic Inhaled Corticosteroid Use in Patients Initiating on Biologic Therapies for Severe Asthma: A Nationwide Cohort Study.

Supratherapeutic Inhaled Corticosteroid Use in Patients Initiating on Biologic Therapies for Severe Asthma: A Nationwide Cohort Study.

Journal: Lung
Published: December 22, 2024

Early Reduction of FeNO on Anti-IL5 Biologics Is Associated With Clinical Remission of Severe Asthma.

Early Reduction of FeNO on Anti-IL5 Biologics Is Associated With Clinical Remission of Severe Asthma.

Journal: Allergy
Published: August 27, 2024

Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma.

Pre-biologic disease trajectories are associated with morbidity burden and biologic treatment response in severe asthma.

Journal: The European respiratory journal
Published: July 30, 2024
Showing 1-12 of 20

Last Updated: 09/26/2026